{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T21:34:41Z","timestamp":1789940081716,"version":"4.0.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,2,22]],"date-time":"2016-02-22T00:00:00Z","timestamp":1456099200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s00280-016-2984-z","type":"journal-article","created":{"date-parts":[[2016,2,22]],"date-time":"2016-02-22T02:26:13Z","timestamp":1456107973000},"page":"733-743","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Population pharmacokinetics and exposure\u2013response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection"],"prefix":"10.1007","volume":"77","author":[{"given":"Anubha","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziad","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffit","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Wustner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia D.","family":"Maltzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce A.","family":"Wallin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,22]]},"reference":[{"key":"2984_CR1","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/00000658-199609000-00005","volume":"224","author":"DJ Sugarbaker","year":"1996","unstructured":"Sugarbaker DJ, Garcia JP, Richards WG et al (1996) Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma\u2014Results in 120 consecutive patients. Ann Surg 224:288\u2013294","journal-title":"Ann Surg"},{"key":"2984_CR2","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636\u20132644","journal-title":"J Clin Oncol"},{"key":"2984_CR3","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/1097-0142(19930715)72:2<410::AID-CNCR2820720216>3.0.CO;2-G","volume":"72","author":"VD Manzini","year":"1993","unstructured":"Manzini VD, Brollo A, Franceschi S et al (1993) Prognostic factors of malignant mesothelioma of the pleura. Cancer 72:410\u2013417","journal-title":"Cancer"},{"key":"2984_CR4","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ijc.2910500308","volume":"50","author":"K Chang","year":"1992","unstructured":"Chang K, Pastan I, Willingham MC (1992) Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 50:373\u2013381","journal-title":"Int J Cancer"},{"key":"2984_CR5","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/01.MP.0000056981.16578.C3","volume":"16","author":"NG Ordonez","year":"2003","unstructured":"Ordonez NG (2003) Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 16:192\u2013197","journal-title":"Mod Pathol"},{"key":"2984_CR6","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1309\/F1B64CL7H8VJKEAF","volume":"124","author":"R Hassan","year":"2005","unstructured":"Hassan R, Laszik ZG, Lerner M et al (2005) Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol 124:838\u2013845","journal-title":"Am J Clin Pathol"},{"key":"2984_CR7","first-page":"3862","volume":"7","author":"P Argani","year":"2001","unstructured":"Argani P, Iacobuzio-Donahue C, Ryu B et al (2001) Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 7:3862\u20133868","journal-title":"Clin Cancer Res"},{"key":"2984_CR8","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/01.pai.00000141545.36485.d6","volume":"13","author":"R Hassan","year":"2005","unstructured":"Hassan R, Kreitman RJ, Pastan I, Willingham MC (2005) Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol 13:243\u2013247","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"2984_CR9","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/00000478-200302000-00002","volume":"27","author":"M Miettinen","year":"2003","unstructured":"Miettinen M, Sarlomo-Rikala M (2003) Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. Am J Surg Pathol 27:150\u2013158","journal-title":"Am J Surg Pathol"},{"key":"2984_CR10","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.lungcan.2009.07.016","volume":"68","author":"R Hassan","year":"2010","unstructured":"Hassan R, Schweizer C, Lu KF et al (2010) Inhibition of mesothelin-CA125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: implications for cancer therapy. Lung Cancer 68:455\u2013459","journal-title":"Lung Cancer"},{"key":"2984_CR11","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1158\/1535-7163.MCT-11-0454","volume":"11","author":"RJ Kelly","year":"2012","unstructured":"Kelly RJ, Sharon E, Pastan I, Hassan R (2012) Mesothelin-targeted agents in clinical trials and in preclinical development. Mol Cancer Ther 11:517\u2013525","journal-title":"Mol Cancer Ther"},{"key":"2984_CR12","first-page":"20","volume":"7","author":"R Hassan","year":"2007","unstructured":"Hassan R, Ebel W, Routhier EL et al (2007) Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun 7:20","journal-title":"Cancer Immun"},{"key":"2984_CR13","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1158\/1078-0432.CCR-10-2275","volume":"16","author":"R Hassan","year":"2010","unstructured":"Hassan R, Cohen SJ, Phillips M et al (2010) Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res 16:6132\u20136138","journal-title":"Clin Cancer Res"},{"key":"2984_CR14","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.1158\/1078-0432.CCR-14-0804","volume":"20","author":"R Hassan","year":"2014","unstructured":"Hassan R, Jahan T, Kindler HL et al (2014) Amatuximab, a chimeric monoclonal antibody to mesothelin in combination with pemetrexed and cisplatin in patients with unresectable pleural mesothelioma: results of a multi-center phase II clinical trial. Clin Cancer Res 20:5927\u20135936","journal-title":"Clin Cancer Res"},{"key":"2984_CR15","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s10637-014-0196-0","volume":"33","author":"Y Fujisaka","year":"2015","unstructured":"Fujisaka Y, Kurata T, Tanaka K et al (2015) Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors. Invest New Drugs 33:380\u2013388","journal-title":"Invest New Drugs"},{"key":"2984_CR16","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1023\/A:1012299115260","volume":"28","author":"SL Beal","year":"2001","unstructured":"Beal SL (2001) Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 28:481\u2013504","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2984_CR17","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2165\/11535960-000000000-00000","volume":"49","author":"NL Dirks","year":"2010","unstructured":"Dirks NL, Meibohm B (2010) Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49:633\u2013659","journal-title":"Clin Pharmacokinet"},{"key":"2984_CR18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/sj.clpt.6100241","volume":"82","author":"MO Karlsson","year":"2007","unstructured":"Karlsson MO, Savic RM (2007) Diagnosing model diagnostics. Clin Pharmacol Ther 82:17\u201320","journal-title":"Clin Pharmacol Ther"},{"key":"2984_CR19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO (2011) Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13:143\u2013151","journal-title":"AAPS J"},{"key":"2984_CR20","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1208\/s12248-009-9112-5","volume":"11","author":"M Bergstrand","year":"2009","unstructured":"Bergstrand M, Karlsson MO (2009) Handling data below the limit of quantification in mixed effect models. AAPS J 11:371\u2013380","journal-title":"AAPS J"},{"key":"2984_CR21","first-page":"e38","volume-title":"Basic concepts in population modeling, simulation, and model-based drug development\u2014Part 2: introduction to pharmacokinetic modeling methods","author":"DR Mould","year":"2013","unstructured":"Mould DR, Upton RN (2013) Basic concepts in population modeling, simulation, and model-based drug development\u2014Part 2: introduction to pharmacokinetic modeling methods. Pharmacometrics & Systems Pharmacology, CPT, p e38. doi: 10.1038\/psp.2013.14"},{"key":"2984_CR22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/11530560-000000000-00000","volume":"24","author":"D Mould","year":"2010","unstructured":"Mould D, Green B (2010) Pharmacokinetics and pharmacodynamics of monoclonal antibodies. Concepts and lessons for drug development. Biodrugs 24:23\u201339","journal-title":"Biodrugs"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-2984-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-016-2984-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-2984-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T06:07:40Z","timestamp":1559023660000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-016-2984-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,22]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["2984"],"URL":"https:\/\/doi.org\/10.1007\/s00280-016-2984-z","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,22]]}}}